Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is making significant strides in precision oncology with its lead candidate ONC010, a nanoparticle-encapsulated inhibitor of PNKP (polynucleotide kinase/phosphatase), an enzyme involved in DNA repair. The company is building the manufacturing and scientific foundation necessary to advance the program toward first-in-human studies, marking a critical step in the development of targeted cancer therapies.
The company has initiated polymer process development and analytical characterization activities in collaboration with Nanosoft Polymers, alongside metabolism studies with Nucro-Technics. These efforts are part of the IND-enabling program designed to support scalable manufacturing, characterize ONC010's metabolic profile, and generate essential data for future pharmacokinetic, toxicology, and regulatory activities. By addressing these key aspects early, Onco-Innovations aims to streamline the path to clinical trials and eventual regulatory approval.
ONC010 is being developed for cancers that may be particularly susceptible to DNA damage response (DDR) approaches. By inhibiting PNKP, the drug disrupts the repair of DNA single-strand breaks, leading to the accumulation of damage and ultimately cell death in tumor cells. The nanoparticle encapsulation is intended to enhance drug delivery and reduce off-target effects, potentially improving the therapeutic index. This approach is particularly relevant in biomarker-selected patient populations, where the presence of specific genetic alterations can predict response to DDR-targeted therapies.
The company's strategy combines targeted PNKP inhibition with advanced nanoparticle drug delivery and AI-driven discovery capabilities. This integrated platform positions Onco-Innovations to identify and develop therapies for cancers that are currently difficult to treat. As precision medicine continues to expand, the ability to match patients with the most effective treatments based on their tumor's genetic profile is becoming increasingly important, and Onco-Innovations is aligning its development efforts accordingly.
The recent advancements reflect a broader trend in oncology toward more personalized and targeted approaches. Traditional chemotherapies often have limited efficacy and significant toxicity, whereas biomarker-driven therapies offer the potential for improved outcomes and reduced side effects. The development of ONC010 could provide a new treatment option for patients with tumors that have specific DNA repair deficiencies, addressing an unmet medical need.
For more information about Onco-Innovations, visit the company's website at https://oncoinnovations.com/. The latest news and updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF.
